Cargando…

Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials

Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown potential neuroprotection in the setting of traumatic brain injury (TBI), spinal cord injury (SCI), and ischemic stroke. Mechanisms currently under investigation include en...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Peter A., Harting, Matthew T., Shah, Shinil K., Day, Mary-Clare, El Khoury, Ramy, Savitz, Sean I., Baumgartner, James, Cox, Charles S.
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956462/
https://www.ncbi.nlm.nih.gov/pubmed/21048846
http://dx.doi.org/10.4061/2010/369578
_version_ 1782188147878133760
author Walker, Peter A.
Harting, Matthew T.
Shah, Shinil K.
Day, Mary-Clare
El Khoury, Ramy
Savitz, Sean I.
Baumgartner, James
Cox, Charles S.
author_facet Walker, Peter A.
Harting, Matthew T.
Shah, Shinil K.
Day, Mary-Clare
El Khoury, Ramy
Savitz, Sean I.
Baumgartner, James
Cox, Charles S.
author_sort Walker, Peter A.
collection PubMed
description Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown potential neuroprotection in the setting of traumatic brain injury (TBI), spinal cord injury (SCI), and ischemic stroke. Mechanisms currently under investigation include engraftment and transdifferentiation, modulation of the locoregional inflammatory milieu, and modulation of the systemic immunologic/inflammatory response. While the exact mechanism of action remains controversial, the growing amount of preclinical data demonstrating the potential benefit associated with progenitor cell therapy for neurological injury warrants the development of well-controlled clinical trials to investigate therapeutic safety and efficacy. In this paper, we review the currently active or recently completed clinical trials investigating the safety and potential efficacy of bone marrow-derived progenitor cell therapies for the treatment of TBI, SCI, and ischemic stroke. Our review of the literature shows that while the preliminary clinical trials reviewed in this paper offer novel data supporting the potential efficacy of stem/progenitor cell therapies for CNS injury, a great deal of additional work is needed to ensure the safety, efficacy, and mechanisms of progenitor cell therapy prior to widespread clinical trials.
format Text
id pubmed-2956462
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-29564622010-11-03 Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials Walker, Peter A. Harting, Matthew T. Shah, Shinil K. Day, Mary-Clare El Khoury, Ramy Savitz, Sean I. Baumgartner, James Cox, Charles S. Stem Cells Int Review Article Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown potential neuroprotection in the setting of traumatic brain injury (TBI), spinal cord injury (SCI), and ischemic stroke. Mechanisms currently under investigation include engraftment and transdifferentiation, modulation of the locoregional inflammatory milieu, and modulation of the systemic immunologic/inflammatory response. While the exact mechanism of action remains controversial, the growing amount of preclinical data demonstrating the potential benefit associated with progenitor cell therapy for neurological injury warrants the development of well-controlled clinical trials to investigate therapeutic safety and efficacy. In this paper, we review the currently active or recently completed clinical trials investigating the safety and potential efficacy of bone marrow-derived progenitor cell therapies for the treatment of TBI, SCI, and ischemic stroke. Our review of the literature shows that while the preliminary clinical trials reviewed in this paper offer novel data supporting the potential efficacy of stem/progenitor cell therapies for CNS injury, a great deal of additional work is needed to ensure the safety, efficacy, and mechanisms of progenitor cell therapy prior to widespread clinical trials. SAGE-Hindawi Access to Research 2010-07-20 /pmc/articles/PMC2956462/ /pubmed/21048846 http://dx.doi.org/10.4061/2010/369578 Text en Copyright © 2010 Peter A. Walker et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Walker, Peter A.
Harting, Matthew T.
Shah, Shinil K.
Day, Mary-Clare
El Khoury, Ramy
Savitz, Sean I.
Baumgartner, James
Cox, Charles S.
Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials
title Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials
title_full Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials
title_fullStr Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials
title_full_unstemmed Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials
title_short Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials
title_sort progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956462/
https://www.ncbi.nlm.nih.gov/pubmed/21048846
http://dx.doi.org/10.4061/2010/369578
work_keys_str_mv AT walkerpetera progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials
AT hartingmatthewt progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials
AT shahshinilk progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials
AT daymaryclare progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials
AT elkhouryramy progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials
AT savitzseani progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials
AT baumgartnerjames progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials
AT coxcharless progenitorcelltherapyforthetreatmentofcentralnervoussysteminjuryareviewofthestateofcurrentclinicaltrials